H.R. 3674: Global Alzheimer’s Initiative Now Act

This bill, titled the Global Alzheimer’s Initiative Now Act, seeks to authorize the participation of the United States in the Davos Alzheimer’s Collaborative (DAC) in order to enhance international efforts to combat Alzheimer's disease and dementia. Key points of the bill include:

Purpose and Findings

The bill highlights the growing prevalence of Alzheimer’s disease and dementia, which currently affects nearly 60 million people worldwide, a number expected to rise to over 150 million by 2050. It cites that:

• Alzheimer's and dementia cases outnumber those of cancer and HIV combined.
• The economic burden of these diseases exceeds $1.3 trillion annually and is projected to double every decade.
• The increase in older populations will place additional stress on healthcare systems, especially in low- and middle-income countries.

Policy Statement

The United States aims to lead global efforts to fight Alzheimer’s disease and dementia, particularly in nations with low and middle-income economies. The goals include:

• Developing effective diagnostics and treatments for diverse populations.
• Promoting international cooperation in health initiatives.
• Leveraging U.S. financial contributions for broader efforts.

Authorization for Participation

The bill authorizes the U.S. to join and support the DAC, which is a collaborative effort established in 2021. Key aspects include:

• The President may designate a representative to serve on DAC’s Advisory Council and Board of Directors.
• The representative should have expertise in development and public health.

Financial Contributions

The bill allows for U.S. financial contributions to DAC as part of the Foreign Assistance Act. Important points include:

• Funding from the U.S. is contingent on DAC obtaining additional funds from other sources.
• U.S. contributions cannot exceed 33% of the total DAC funding from all sources during the fiscal years 2026 to 2030.

Reporting Requirements

The President is required to report to Congress within 180 days of the bill's enactment and annually thereafter, providing:

• Details about U.S. financial contributions to DAC.
• Information about U.S. governance participation in DAC.
• A summary of both private and governmental contributions.
• An overview of how DAC participation aligns with U.S. strategies to combat Alzheimer’s disease and support global health initiatives.

Conclusion

The bill emphasizes the need for international collaboration to improve Alzheimer's research, diagnosis, and treatment, highlighting the importance of addressing a growing health crisis affecting millions of people globally.

Relevant Companies

None found